GuideAI Health Corp. · NEO:GDAI
GuideAI Health — Investor Presentation (2026)
22 slides from GuideAI Health's investor presentation, Oct 8, 2026
Slide 1: Improving Vascular Health with AI-driven Early Disease Detection & Surgical Precision
I NVEST OR PRESE NTATI ON Improving Vascular Health with AI-driven Early Disease Detection & Surgical Precision 230 Million Patients. FDA-Cleared Triage AI. One Company. CBOE: GDAI
Slide 2: Legal Disclaimer
Confidential - Do Not Distribute Legal Disclaimer Terms of Use Forward-looking statements are based on management’s c urrent expec tations, ass umptions, and beliefs regarding future events and are subject to a number of known and unknown risks, uncertainties, and other This investor presentation is
Slide 3: Investment Highlights
Confidential - Do Not Distribute Investment Highlights $200B+ Peripheral Arterial Disease (PAD) Problem1 200+ Global Hospital LOIs Peripheral Arterial Disease (PAD) is widely underdiagnosed and contributes Led by ex perienced radiologists, AI engineers, and healthcare operators. to more than $200B i
Slide 4: A Proven Blueprint. An Unaddressed Market.
THE I NVE STMEN T TH ESIS A Proven Blueprint. An Unaddressed Market. H EARTF L OW IN C. G UID E AI H EA LT H $176M Revenue1 (FY 2025) Early-Stage Opportunity 2025) Targeting Multiple Vascular Diseases (Starting Built on AI + Coronary Imaging with Peripheral Arterial Disease) 200M patient population
Slide 5: At a Glance
SI DE-BY -SI DE C OMP AR ISON Confidential - Do Not Distribute At a Glance G uideA I H ealth H eartFlow VascularAssist · PAD · Ea rly- detec tion A I H eartFlow One · C AD · AI card iac im ag ing Peripheral arterial disease — arteries of the limbs and extremities Focus Coronary artery disease — the
Slide 6: Peripheral Arterial Disease: 230 Million Patients, Routinely Missed
THE P ROBLEM Peripheral Arterial Disease: 230 Million Patients, Routinely Missed 230M1 People with PAD globally 63%+2 of significant cardiovascular findings go unreported on routine CT 1M+3 Amputations annually — can be preventable PAD progresses silently. By the time it's detected, 1https://www.aha
Slide 7: 50 CT Scans Per Day. 5 Images Per Second. Disease Gets Missed.
ROOT C AU S E 50 CT Scans Per Day. 5 Images Per Second. Disease Gets Missed. Significant arterial narrowing (50%+ stenosis) is often missed, under-reported due to poorly characterized by Radiologists THE RA DIOLOGIST R EA LITY • A single CT scan = hundreds of individual images • Average workload: 50
Slide 8: Behind Every Missed Scan Is a Patient
W HY IT M ATTE RS Behind Every Missed Scan Is a Patient WI T H O UT E A R L Y DE T E CT I ON WI TH G UI DEA I E ARL Y D ETECTI O N Silent disease progression AI can flag early vascular markers Critical limb ischemia Physicians bettered equipped to intervene early Amputation Potential to reduce amput
Slide 9: Four Forces That Make This the Right Moment
S TRU CTU RA L TAI L WI NDS Four Forces That Make This the Right Moment Diabetes Epidemic AI Imaging Market IDF projects 853M adults with diabetes by 2050 — $2.2B in 2026, forecast $17.8B by 2033 at 34.8% PAD's primary risk factor. Every new diagnosis is a Compound Annual Growth Rate (CAGR). Deep- p
Slide 10: VascularAssist— Finding What Others Miss
G UI DE AI HEA LT H S O L U T IO N VascularAssist— Finding What Others Miss No New Hardware AI-Powered Detection Actionable Output Designed to integrate with existing CT Deep learning trained on data from Structured, standardized reports. imaging infrastructure, with the goal 2,100+ hospitals. Mimic
Slide 11: HeartFlow Built $176M/Year. GuideAI Is at Day Zero of the Same Curve.
THE P ROOF OF CONC EPT HeartFlow Built $176M/Year. GuideAI Is at Day Zero of the Same Curve. Curve. The roadmap exists. The question is who applies it next. GuideAI has the team, the data, and the technology to follow it. HeartFlow Revenue Trajectory HeartFlow FY2025 $176M 1 Revenue 240 190 140 40%
Slide 12: The Valuation Gap Is the Opportunity
M AR KET OPP ORTUN ITY The Valuation Gap Is the Opportunity Addressable medical imaging AI market $6B2 (28% CAGR) 230M1 $20B3 Total AI in medical imaging by 2029 Patients with Peripheral Arterial Disease $233B+4 Annual US healthcare cost burden of PAD HeartFlow targets 200M coronary patients, valued
Slide 13: Every Competitor Is in a Different Anatomy
C OMP ETITI VE LA NDSC A PE Every Competitor Is in a Different Anatomy C om p any Foc us Area PA D C overag e Viz.ai Stroke / Brain None Aidoc Acute radiology triage None Cleerly Coronary arteries None HeartFlow Coronary arteries None G uid eA I H ealth P ER IP H ER A L V A S C U L A R FIR S T M O V
Slide 14: Recurring SaaS Revenue That Compounds With Each Disease Area
BU SIN ESS MOD EL Recurring SaaS Revenue That Compounds With Each Disease Area 1 2 3 Hospital Signs Contract Annual SaaS Fee Revenue Expands AI platform integrated into radiology Per-site recurring revenue, high- Each new disease area adds to the workflow margin software same contract Up to $3M / ye
Slide 15: 200+ Hospital LOIs. World-Class Data. Named Partners.
V AL I DA TION & PA RTNER S HIP S 200+ Hospital LOIs. World-Class Data. Named Partners. vRad Partnership Advocate Health LOI Academic Medical Centres Exclusive access to 1 billion+ medical 69 hospitals. 6M patients served Clinical validation studies underway at images from 2,100+ hospitals. Largest
Slide 16: Four Events That Will Move This Story
NEA R -TER M C ATA L YSTS Four Events That Will Move This Story 1 FDA Approved VAOT — 510k Clearance Commercial launch trigger Obtained 2 First Signed Hospital Contract First revenue visibility Post-FDA 3 CarotidAssist FDA Clearance Second product, second revenue layer Expected Q1 2027 4 Internation
Slide 17: FDA Clears GuideAI's AI Software for Vascular Disease
V as c ul a rA ss i st O c cl u si on T r i a ge (VA O T ) | F DA 510 (k ) cl e a ra nc e | J une 202 6 FDA Clears GuideAI's AI Software for Vascular Disease T he U.S. Fo od and D rug Ad m inistratio n (FD A) g ra nted 510(k) c learanc e to Guid eA I H ealth for its artific ial 1 intellig enc e soft
Slide 18: How Well It Works and What It Means for GuideAI
How Well It Works and What It Means for GuideAI How accurate it is (clinical How it fits into hospitals What it means for GuideAI performance testing) • In testing, VAOT correctly flagged up • VAOT runs inside the imaging • This is a defining regulatory to 95% of patients who had systems hospitals a
Slide 19: Three Moats That Are Hard to Replicate
D EF ENS I BL E T ECH NO L O GY Three Moats That Are Hard to Replicate D AT A C LI NIC AL OR IG IN WO RK FL OW IN TE G RAT I ON Exclusive access to 1B+ images from Built by interventional radiologists Designed to plug into existing hospital 2,100+ hospitals via vRad. More data who saw the problem fi
Slide 20: Clear Path to Market
ROA D MA P TO COM M ERC IA LIZA TION Clear Path to Market Q2 2026 Q3 2026 Q4 2026 Q1 2027 Q2 2027 ↗ Execute initial ↗ Apply for ↗ Launch of the ↗ Achieve FDA ↗ Achieve FDA commercial breakthrough Elevate Platform 510(k) clearance 510(k) clearance contracts and designation of at RSNA 2026 for VAPAD,
Slide 21: Built by the Clinicians Who Saw What Was Being Missed
TH E T EAM Built by the Clinicians Who Saw What Was Being Missed GuideAI was founded by interventional radiologists who spent careers reviewing imaging and repeatedly seeing early PAD go undetected. That clinical insight drives everything. R a j S h ah , M D M B A L u ke H ig g ins, M D P hD C h ief
Slide 22: Thank you
Thank you 230 Million Patients. FDA-Cleared Triage AI. One Company. CBOE: GDAI